ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1889

Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up

Julio Ramirez1, Andrea Cuervo Aguilera 2, Raquel Celis 3, Virginia Ruiz-Esquide 3, Raul Castellanos-Moreira 4, Jose Gomez-Puerta 5, Raimon Sanmarti 5 and Juan Cañete 5, 1Hospital Clinic, Barcelona, Spain, Barcelona, Spain, 2Hospital Clínic Barcelona, Spain, Barcelona, Spain, 3Hospital Clínic, Barcelona, Spain, 4Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, 5Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biomarkers, Doppler ultrasound and Synovial Immune Biology, radiology, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remission

Methods: RA patients in clinical remission (defined as DAS28-ESR < 2.6 for > 6 months) were selected. Clinical, epidemiological and serological data were analyzed. A MRI of dominant hand and an ultrasound assessment of knees and hands were performed at baseline and at 48 weeks. Serum levels of inflammation and angiogenesis biomarkers were determined by Quantibody® Human Array at baseline and 48 weeks. A synovial biopsy was performed in patients with subclinical synovitis. Patients were followed up for 5 years. Clinical and radiological data (hands and feet X-rays) were collected. Clinical relapse was defined as loss of remission status (DAS28 > 2.6) leading to a therapeutic intervention. Treatment change was defined as the change in csDMARD or biological therapy of RA. Radiographic progression was defined as the change in the SvH index at 5 years >10.47 (SDD).

Results: 60 patients fulfilling ACR 2010 criteria for RA and DAS28< 2.6 were included. 1/3 also met remission criteria for SDAI (33.3%), CDAI (31.6%) and ACR (35%). 78.3% of the patients were women. Mean age was 53 years and the disease duration was 110 months. 81.6% were ACPA +. 26% were taking oral prednisone, 76% DMARDs and 45% biological therapies. At baseline, 67% had PD signal and 48% met a more stringent criteria for subclinical synovitis (UdAS: SH > 2 + PD). After 5 years of follow-up, 44 (73.3%), 11 (18.3%), 9 (15%) and 10 (16.6%) patients remained in remission according to DAS28, SDAI, CDAI and ACR criteria, respectively.   29 patients (48.3%) had flares at any time during the 5 years of follow-up. In the multivariate analysis, the variables that were related to clinical relapse were BMI (OR 1.8 CI 95% 1.2-2.7), TNFalpha levels at baseline (OR 32.4, CI 95% 1.9-546.2), the fisrt year change in CXCL16 levels (OR 1.05 CI 95% 1-1.1) and ESR (OR 2.48 CI 95% 1-6.1). Patients who flared during the follow-up had a significantly higher number of mast cells (p=0.02). Regarding to change in treatment, 20 patients (33.3%) changed DMARDs or biological therapy at any time during the 5 years of follow-up. In the logistic regression analysis, BMI (OR 1.3 CI 95% 1-1.7), biological therapy (OR 24.7 CI 95% 2.3-257.2), progression of erosions by MRI during the first year (OR 1.2, CI 95% 1-1.3) and the rate of progression of calprotectin serum levels during the first year (OR 2.8, CI 95% 1-8.2) were the main factors that predicted the change in baseline therapy after 5 years of follow-up . Finally, only 6 patients (10%) had X-Ray progression according to the SvdH index.  The number of macrophages and T cells in synovial tissue at baseline was much higher in patients with radiological progression. Likewise, the first-year rate of bone edema was significantly higher in patients with structural progression (p = 0.04)

Conclusion: 27% of RA patients lost clinical remission (DAS28) after 5 years of follow-up. BMI, serum TNFa levels, and first-year rate of CXCL16 and VSG levels were predictors of joint flares.  Baseline BMI, use of biological therapy, MRI erosions and calprotectin levels predicted the change of baseline therapy for RA. Only 10% of patients had radiological progression along the study.


Disclosure: J. Ramirez, None; A. Cuervo Aguilera, None; R. Celis, None; V. Ruiz-Esquide, None; R. Castellanos-Moreira, None; J. Gomez-Puerta, None; R. Sanmarti, None; J. Cañete, Eli Lilly and Company, 5, Janssen, 5, 8, Novartis, 5, 8, Mylan, 5, Pfizer, 5, UCB, 5.

To cite this abstract in AMA style:

Ramirez J, Cuervo Aguilera A, Celis R, Ruiz-Esquide V, Castellanos-Moreira R, Gomez-Puerta J, Sanmarti R, Cañete J. Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/biomarkers-of-clinical-relapse-and-radiological-progression-in-patients-with-rheumatoid-arthritis-in-remission-observational-study-of-5-years-of-follow-up/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biomarkers-of-clinical-relapse-and-radiological-progression-in-patients-with-rheumatoid-arthritis-in-remission-observational-study-of-5-years-of-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology